^
    TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research. It provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP.
    Cancer:
    Pancreatic Cancer, Solid Tumor
    Gene:
    MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Next-Generation Sequencing (NGS)